Search results for "Highlights"
Meta-analysis examines risks, benefits of third-line antihyperglycemic drugs added to combination therapy
Antihyperglycemic drugs added to metformin/sulfonylurea combination therapy in adults with type 2 diabetes vary in efficacy and risks for adverse effects, according to a recent study.
https://diabetes.acponline.org/archives/2015/08/14/1.htm
14 Aug 2015
Diabetes prevalence remains high in U.S. adults
The estimated prevalence of diabetes among U.S. adults ranged between 12% and 14% in 2011-2012, according to a recent study.
https://diabetes.acponline.org/archives/2015/09/11/3.htm
11 Sep 2015
Metformin potentially underused among patients with mild kidney disease, study finds
More patients would be eligible for metformin use if estimated glomerular filtration rate were used to define kidney disease rather than serum creatinine, a recent study concluded.
https://diabetes.acponline.org/archives/2015/09/11/2.htm
11 Sep 2015
Extending DAPT for more than 1 year shows benefit in diabetic patients
Extended dual antiplatelet therapy (DAPT) was associated with lower rates of death and myocardial infarction in patients with diabetes who received first-generation drug-eluting stents, but not those without diabetes, a study found.
https://diabetes.acponline.org/archives/2015/09/11/1.htm
11 Sep 2015
Review compares once-weekly GLP-1 receptor agonists to other diabetes meds
Once-weekly glucagon-like peptide 1 (GLP-1) receptor agonists lower HbA1c without increasing body weight, a review found.
https://diabetes.acponline.org/archives/2015/10/09/2.htm
9 Oct 2015
Studies offer support for home use of artificial pancreas in type 1 diabetes
Home use of a closed-loop insulin delivery system, or artificial pancreas, appeared to be effective in patients with type 1 diabetes, according to 2 recently published reports conducted under regular living conditions.
https://diabetes.acponline.org/archives/2015/10/09/3.htm
9 Oct 2015
Empagliflozin associated with reduced mortality risk in patients with cardiovascular disease
Patients with type 2 diabetes and cardiovascular disease who received empagliflozin had lower rates of cardiovascular-related and all-cause mortality than those on placebo, an industry-funded study found.
https://diabetes.acponline.org/archives/2015/10/09/1.htm
9 Oct 2015
DPP-4 inhibitors associated with lower mortality and cardiac risk than sulfonylureas as add-on therapy, study finds
When added to metformin, DPP-4 inhibitors were associated with reduced risks for all-cause death and stroke but did not appear to alter the risks for myocardial infarction and hospitalization for heart failure relative to sulfonylureas.
https://diabetes.acponline.org/archives/2015/11/13/3.htm
13 Nov 2015
Mortality in diabetes may vary greatly by age, glycemic control, renal complications
Patients who were under age 55 faced a more substantial increase in mortality risk from having diabetes than older patients.
https://diabetes.acponline.org/archives/2015/11/13/2.htm
13 Nov 2015
New algorithm may help physicians set glycemic targets for patients with diabetes
Researchers created a new algorithm to help choose target HbA1cs for patients with diabetes and compared the results to experts' advice.
https://diabetes.acponline.org/archives/2015/11/13/1.htm
13 Nov 2015